Company: PGEN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001356090-25-000034
Chunk: 23

Company: PRECIGEN, INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
 and outstanding as of September 30, 2025 and December 31, 2024, respectively (aggregate liquidation preference of zero as of September 30, 2025 and $79,000 as of December 31, 2024).— 28,218 Shareholders' equityCommon stock, no par value, 700,000,000 shares authorized as of September 30, 2025 and 400,000,000 shares authorized as of December 31, 2024; 353,810,556 shares and 292,869,097 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.— — Additional paid-in capital2,359,689 2,129,207 Accumulated deficit(2,317,845)(2,090,706)Accumulated other comprehensive income24 12 Total shareholders' equity 41,868 38,513 Total liabilities, mezzanine equity and shareholders' equity$171,264 $145,266 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Table of Contents

 Precigen, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

(Amounts in thousands, except share and per share data)Three Months Ended  September 30,Nine Months Ended  September 30,2025202420252024RevenuesCollaboration and licensing revenue$1,818 $— $1,818 $— Product revenues162 66 406 235 Service revenues942 886 2,838 2,478 Other revenues— 1 57 22 Total revenues2,922 953 5,119 2,735 Operating ExpensesCost of products and services1,035 1,009 3,227 3,098 Research and development12,377 11,370 34,343 41,312 Selling, general and administrative23,991 9,836 52,483 30,293 Impairment of goodwill— — 3,907 1,630 Impairment of other noncurrent assets— — — 32,915 Total operating expenses37,403 22,215 93,960 109,248 Operating loss(34,481)(21,262)(88,841)(106